key: cord-0735009-5cixyvqa authors: El-Tahan, Mohamed R. title: The emerging role of bivalirudin for therapeutic anticoagulation in COVID-19 patients requiring ECMO Support: Is it time to change the routine practice? date: 2021-11-10 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2021.11.003 sha: e60d67c6c25042c25e48012bd346d9d8608bdad4 doc_id: 735009 cord_uid: 5cixyvqa nan The emerging role of bivalirudin for therapeutic anticoagulation in COVID-19 patients requiring ECMO Support: Is it time to change the routine practice? Mohamed patient. [6] In this issue of the JCVA, Trigonis et al. [7] presented the results of a retrospective case-control comparative study on the efficacy and safety of protocol-based therapeutic anticoagulation using different bivalirudin dosing rates in 42 patients receiving venovenous (VV) ECMO secondary to non-COVID-19 and COVID-19 infection. The main objective of this single-center study was to better describe the pharmacology of bivalirudin in COVID-19 ECMO patients compared to the non-COVID patients. [7] This study is on time of the need to test the efficacy of using Bivalirudin for anticoagulation in COVID-19 patients receiving VV-ECMO. Compared with the non-COVID-19, patients in the COVID-19 group received higher median and maximum bivalirudin infusion rates to achieve consistent activated partial thromboplastin time (aPTT) levels at a frequency more remarkable than the non-COVID patients despite using the same anticoagulation protocol. [7] In this study, [7] the authors collected the data from patients over one year starting from June 2019. Of note, the first case of COVID-19 infection was identified in the US, the authors' centerbased country, on January 22, 2020. This study did not include any randomization or blinding. Another retrospective study in the US included a single group of 33 COVID-19 patients receiving bivalirudin while on ECMO over nine months from February 2020. [8] The two studies [7, 8] had similar institutional protocols for changing the rate of bivalirudin infusion and therapeutic target of aPTT of 60 to 80 seconds but with different aPTT ranges for changing the bivalirudin infusion rate. Compared with Bissell et al., [8] difference between the peak infusion rates of Bivalirudin in these two studies [7, 8] raises a concern on the need for a well-designed dose-response study to evaluate the optimum infusion rate to maintain the balance between the risks of thrombosis and bleeding. The incidence of intracranial, intraocular, and gastrointestinal bleeding, defined as an acute blood loss for which the patient was transfused for hemoglobin level less than 7 g/dL or associated hemodynamic compromise, and deep venous thrombosis were similar in the two groups. [7] However, caution should be exercised in interpreting the safety of using bivalirudin in COVID-19 patients. First, this study [7] was not powered to test the incidence of bivalirudin-induced complications. Second, the authors did not consider the ELSO criteria for identifying major and minor bleeding events [ Table 1 ]. Third, no data is available on the volume of blood derivatives transfused or rates of significant circuit or component clots, necessitating a change of the ECMO circuit or circuit component. Bivalirudin would be a good alternative to heparin use during the use of ECMO in patients with HIT, [3, 9] however, in the study of Trigonis et al., [7] , patients were not tested for HIT as bivalirudin was used routinely for all patients receiving ECMO at the authors' center. That would limit the generalizability of the present results among different worldwide centers where the use of Bivalirudin is only limited to the patients with HIT because of its high cost. Several previous studies compared the use of unfractionated heparin and bivalirudin for anticoagulation during the use of ECMO, but they have variable designs and numbers of included patients. [12] [13] [14] Seelhammer et al. [10] demonstrated a lower mortality rate in the adult group receiving bivalirudin than the use of heparin for anticoagulation in a large retrospective study including 424 patients requiring ECMO, 21% of them were pediatric. However, this difference was not reported among pediatric patients. Rivosecchi et al. [11] reported significant decreases in the incidence of major bleeding events and ECMO circuit thrombotic complications and volume of packed red blood cells, fresh frozen plasma, and platelet transfusion in 133 patients who received bivalirudin for anticoagulation during the use of ECMO compared with 162 patients received heparin. Smaller studies failed to report similar differences in terms of bleeding or thrombotic complications. [12] [13] Future research also needs to consider the concern on the reported resistance to bivalirudin in patients receiving ECMO. [14] The authors also reported double the cost of using bivalirudin in patients with COVID-19 in addition to the expected added costs of longer times on using ECMO and ICU stays than those with non-COVID-19 ARDS patients. [7] Ranucci et al. demonstrated that compared with heparin use, there was a trend towards a lower cost of using Bivalirudin in adults and a statistically significantly lower cost in pediatric patients receiving post-cardiotomy ECMO. [15] A costanalysis study is needed to define the affordability of routine using bivalirudin anticoagulation for ECMO patients with COVID-19. aPTT is widely accepted as the standard test to monitor bivalirudin therapy during the use of ECMO. Thromboelastometry (ROTEM)-included-intrinsic (INTEM) coagulation pathway had a moderate correlation with simultaneously measured aPTT with bivalirudin anticoagulation in pediatric patients on either ECMO or ventricular assist device. [16] Contradictory discordance between the two methods was reported in critically ill adult patients receiving ECMO support. [17] The role of using ROTEM to monitor bivalirudin therapy for adult COVID-19 patients on ECMO is unclear. In conclusion, although using Bivalirudin has merit in maintaining therapeutic anticoagulation in COVID-19 patients who need ECMO support, it might be a bit early to change the routine use of unfractionated heparin for patients without HIT. Larger prospective randomized-controlled studies are required to corroborate the findings of Trigonis et al. [7] and confirm the safety and efficacy of bivalirudin compared with heparin in COVID-19 patients receiving ECMO support. Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports Role of Bivalirudin for anticoagulation in adult perioperative cardiothoracic practice Bivalirudin and post-cardiotomy ECMO: a word of caution. Crit Care Eleven years of venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: From H1N1 to SARS-CoV-2 Experience and perspectives of a national referral center Bivalirudin for maintenance anticoagulation during venovenous extracorporeal membrane oxygenation for COVID-19 Efficacy of bivalirudin for therapeutic anticoagulation in COVID-19 patients requiring ECMO support Evaluation of Bivalirudin as the primary anticoagulant in patients receiving extracorporeal membrane oxygenation for SARS-CoV-2-associated acute respiratory failure A comparison of bivalirudin and heparin for patients on extracorporeal membrane oxygenation Comparison of Bivalirudin versus heparin for maintenance systemic anticoagulation during adult and pediatric extracorporeal membrane oxygenation Comparison of anticoagulation strategies in patients requiring venovenous extracorporeal membrane oxygenation: Heparin versus Bivalirudin Heparin vs. Bivalirudin anticoagulation for extracorporeal membrane oxygenation Extracorporeal membrane oxygenation complications in heparin-and Bivalirudin-treated patients Bivalirudin resistance in a patient on venovenous extracorporeal membrane oxygenation with a therapeutic response to argatroban Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation Monitoring bivalirudin therapy in children on extracorporeal circulatory support devices: Thromboelastometry versus routine coagulation testing Discordance between ROTEM ® clotting time and conventional tests during unfractionated heparin-based anticoagulation in intensive care patients on extracorporeal membrane oxygenation The Extracorporeal Life Support Organization (ELSO) Accessed on Tables Table 1: The ELSO criteria for identifying major and minor bleeding events. Developed fromThe ELSO Anticoagulation Guideline.[21] Major bleeding 1. Clinically overt bleeding is associated with any of the following:-Hemoglobin falls of at least 2 g/dl in 24 hours.-A greater than 20 ml/kg over 24 hours.-Transfusion requirement of one or more 10 ml/kg PRBC transfusions over that same period.2. Retroperitoneal bleeding.3. Pulmonary bleeding.4. Intracranial bleeding. A less than 20 ml/kg/day requires transfusion of one 10 ml/kg packed red blood cells transfusion or less.